Company Valuation: Cardiol Therapeutics Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 142 43.96 71.77 151 130.4 209.8 - -
Change - -69.05% 63.28% 110.34% -13.65% 60.93% - -
Enterprise Value (EV) 1 142 43.96 36.84 120.4 108.9 194.8 199.5 209.8
Change - -69.05% -16.19% 226.78% -9.5% 78.79% 2.44% 5.14%
P/E -3.19x -1.41x -2.5x -3.63x -3.36x -3.63x -7.48x 47.5x
PBR - - 2.55x 6.18x 6.41x 9.89x 18.1x -
PEG - 0x 0.2x -0.2x 0.1x -0.2x 0.1x -0x
Capitalization / Revenue 1,803x - - - - - 63.2x 5.78x
EV / Revenue 1,803x - - - - - 60.1x 5.78x
EV / EBITDA -4.74x -1.07x -1.25x -3x -3.18x -7.57x -12.6x -10.2x
EV / EBIT -3.67x -1.06x -1.24x -2.99x -3.17x -5.55x -7.43x 43.5x
EV / FCF -6.03x - -1.46x -4.8x -4.56x -9.59x -42.6x -
FCF Yield -16.6% - -68.5% -20.8% -21.9% -10.4% -2.35% -
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 -0.73 -0.49 -0.44 -0.51 -0.39 -0.48 -0.2325 0.0367
Distribution rate - - - - - - - -
Net sales 1 0.0788 - - - - - 3.321 36.32
EBITDA 1 -29.95 -41.12 -29.54 -40.11 -34.21 -25.72 -15.88 -20.62
EBIT 1 -38.66 -41.34 -29.79 -40.28 -34.32 -35.09 -26.87 4.821
Net income 1 -31.64 -30.93 -28.13 -36.68 -33.82 -35.21 -30.57 -8.68
Net Debt 1 - - -34.93 -30.58 -21.42 -15.01 -10.26 -
Reference price 2 2.330 0.690 1.100 1.850 1.310 1.740 1.740 1.740
Nbr of stocks (in thousands) 60,954 63,703 65,247 81,603 99,514 115,272 - -
Announcement Date 3/23/22 3/28/23 4/1/24 3/31/25 3/31/26 - - -
1CAD in Million2CAD
Estimates

P/E, Detailed evolution

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
-3.79x - -7.57x - 149M
31.99x5.69x17.6x1.03% 46.06B
-22.96x333.54x-20.89x-.--% 38.91B
48.28x4.86x31.12x-.--% 35.57B
24.16x2.71x11.7x-.--% 33.13B
26.27x7.71x19.36x0.43% 26.42B
31.03x5.02x22.85x-.--% 15.08B
24.17x2.07x9.1x1.09% 14.08B
23.64x1.89x11.43x-.--% 12.81B
Average 20.31x 45.44x 10.52x 0.32% 24.69B
Weighted average by Cap. 22.06x 62.31x 11.80x 0.33%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. CRDL Stock
  4. Valuation Cardiol Therapeutics Inc.